Physician profile

Robert Redfield

Transplant Surgery · Orange, CA

NPI 1326195082

$65,438.85

in general payments reported to CMS, 2019-2025

14 companies · $1,811 in 2025

The $1,811 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$5,434.67
Food and Beverage$1,048.18
Travel and Lodging$657.81

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Veloxis Pharmaceuticals, INC. $33,109.82 2020-2022
Genentech, INC. $12,577.50 2020-2023
Regeneron Pharmaceuticals, INC. $10,964.31 2019-2025
Intuitive Surgical, INC. $3,777.66 2021-2024
Medical Device Business Services, INC. $2,609.04 2021-2022
Ethicon US, LLC $1,008.41 2021-2023 Echelon Flex
Sanofi-Aventis U.S. LLC $390.65 2024-2025
Zoll Medical Corporation $366.67 2024 Defibrillator
Dilon Technologies, INC. $246.60 2024-2025 Hemoblast Bellows
Paragonix Technologies, INC. $175.25 2024-2025 Sherpapak, Pancreaspak, Liverguard
Eurofins Viracor, LLC $149.76 2024
Pfizer INC. $63.18 2019

2 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$739.39 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert Redfield

$65,438.85

in general payments reported 2019-2025

Years
2019-2025
Top company
Veloxis Pharmaceuticals, INC.
Context
The $1,811 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).

https://glasscript.com/doctor/856287/robert-redfield

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.